Study Identifies Risk Factors For Reduced Likelihood Of DAA Prescription Among People With HCV Infection Entering OUD Treatment

HCPlive (7/15, Brooks) reports, “Among people with hepatitis C virus (HCV) infection entering opioid use disorder (OUD) treatment in the United States, female sex and recent pregnancy are independent risk factors for reduced likelihood of direct-acting antiviral (DAA) prescription, according to findings from a recent study.” The research “found significant differences in DAA prescription between men and women, most starkly in women with recent pregnancy compared to men and women without recent pregnancy.” According to HCPlive, “given findings illustrating challenges in postpartum linkage to HCV care, investigators suggest pregnancy could be a window of opportunity for HCV treatment that merits further research.” The findings were published in O&G Open.